Get the Stockscreener App
14.69
8.81%
1.19
After Hours:
14.65
-0.04
-0.27%
Tonix Pharmaceuticals Holding Corp stock is traded at $14.69, with a volume of 877.34K.
It is up +8.81% in the last 24 hours and up +7.94% over the past month.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
See More
Previous Close:
$13.50
Open:
$14
24h Volume:
877.34K
Relative Volume:
2.20
Market Cap:
$208.68M
Revenue:
$13.11M
Net Income/Loss:
$-124.02M
P/E Ratio:
-1.0301
EPS:
-14.261
Net Cash Flow:
$-107.25M
1W Performance:
+18.47%
1M Performance:
+7.94%
6M Performance:
-15.62%
1Y Performance:
-22.19%
1-Day Range:
$14.00
$15.18
1-Week Range:
$12.21
$15.18
52-Week Range:
$11.60
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
14.69 | 191.77M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Secures GPO Agreement Covering 35 Million Lives for TONMYA - Scott Coop
Tonix Pharmaceuticals Secures Major Commercial Coverage for TONMYA®, Expanding Access to Fibromyalgia Treatment for 35 Million U.S. Patients - Minichart
Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits
Tonix Pharmaceuticals stock gains on GPO coverage deal By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals stock gains on GPO coverage deal - Investing.com
Tonix stock rises on commercial payer coverage (TNXP:NASDAQ) - Seeking Alpha
Tonix Pharma Expands TONMYA Coverage Across U.S. Payers - TipRanks
Tonix secures GPO coverage for fibromyalgia drug TONMYA - Investing.com
35 million insured Americans gain access to Tonix fibromyalgia drug - Stock Titan
Tonix (NASDAQ: TNXP) secures TONMYA fibromyalgia coverage for 35M insured lives - Stock Titan
Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients - Yahoo! Finance Canada
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Upgraded by TD Cowen - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Cash per share of Tonix Pharmaceuticals Holding Corp. – DUS:TPM0 - TradingView
Tonix Pharmaceuticals (TNXP) to Release Quarterly Earnings on Monday - MarketBeat
TD Cowen initiated coverage on Tonix Pharma with a new price target - Quantisnow
TD Cowen initiates Tonix Pharma stock with buy rating, $22 target - Investing.com India
TD Cowen initiates Tonix Pharma stock with buy rating, $22 target By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Holding (TNXP) price target decreased by 15.76% to 55.42 - MSN
Tonix Pharmaceuticals Holding Corp. Files Form 8-K Current Report with NASDAQ Listing Details (May 1, 2026) - Minichart
Tonix Pharmaceuticals (NASDAQ: TNXP) gives early look at Q1 2026 sales - Stock Titan
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharmaceuticals (TNXP) Proxy filing Summary - Quartr
Tonix Pharmaceuticals (TNXP) Announces Phase 2 Study Plans for L - GuruFocus
Tonix plans Phase 2 Lyme disease prevention study in 2027 - Investing.com UK
Tonix plans Phase 2 Lyme disease prevention study in 2027 By Investing.com - Investing.com Australia
Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program - TipRanks
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symp - The Manila Times
Tonix (NASDAQ: TNXP) plans Phase 2 Lyme antibody study for 2027 - Stock Titan
A two-dose Lyme prevention antibody is planned for a U.S. field study - Stock Titan
Tonix Pharmaceuticals Announces Presentation of Phase 1 - GlobeNewswire
Tonix Pharmaceuticals stock hits new 52-week low: What's driving the action? - MSN
Tonix Pharmaceuticals Stock Jumps Into Retail Spotlight After $25M Buyback Boost — Traders See ‘Blueprint For Rerating’ - MSN
(TNXP) Risk Channels and Responsive Allocation - Stock Traders Daily
Tonix Pharmaceuticals Holding Corp (STU:TPM0) Stock Price & 30 Year Financial Data - GuruFocus
Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - MarketBeat
Tonix Pharmaceuticals Showcases Promising Preclinical Immuno-Oncology Advances with TNX-1700 and TNX-4700 at AACR 2026 1 - Minichart
Tonix Pharma Highlights Preclinical Progress in Oncology Pipeline - TipRanks
Preclinical cancer data for Tonix (NASDAQ: TNXP) TNX-1700 and TNX-4700 - Stock Titan
Tonix Pharmaceuticals Presents Updates on Preclinical - GlobeNewswire
Tonix Pharmaceuticals (NASDAQ:TNXP) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
(TNXP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development - Sahm
Tonix publishes pharmacokinetic study on fibromyalgia drug By Investing.com - Investing.com Australia
Tonix Pharmaceuticals (TNXP) Reports Positive Findings on TNX-10 - GuruFocus
Tonix publishes pharmacokinetic study on fibromyalgia drug - Investing.com
Tonix Pharmaceuticals Announces Publication of Steady-State - GlobeNewswire
Analyst Upgrade: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear marketWeekly Earnings Recap & Reliable Price Breakout Alerts - baoquankhu1.vn
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):